<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Pediatric <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with <z:mp ids='MP_0004026'>monosomy</z:mp> 7 is associated with poor disease-free survival when treated by conventional chemotherapy, immunosuppression or supportive measures </plain></SENT>
<SENT sid="1" pm="."><plain>Hematopoietic stem cell transplant (HSCT) may improve outcomes; however, data to support this are limited </plain></SENT>
<SENT sid="2" pm="."><plain>To better understand the curative potential of HSCT in these patients, <z:hpo ids='HP_0000001'>all</z:hpo> cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with <z:mp ids='MP_0004026'>monosomy</z:mp> 7 treated by two transplant programs (1992 to present) were reviewed </plain></SENT>
<SENT sid="3" pm="."><plain>A total of 16 patients were treated, <z:hpo ids='HP_0000001'>all</z:hpo> by allogeneic HSCT </plain></SENT>
<SENT sid="4" pm="."><plain>Primary diagnoses were <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (N = 5), <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> (N = 3), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (N = 5) and therapy-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (N = 3) </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 11 patients (69%) survive event-free at 2 years with median follow-up of 986 days (range 330-2011 days) </plain></SENT>
<SENT sid="6" pm="."><plain>Toxicity caused <z:hpo ids='HP_0011420'>deaths</z:hpo> of the five nonsurviving patients, four of whom were transplanted with active <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Allogeneic HSCT is effective therapy for <z:e sem="disease" ids="C0220621" disease_type="Neoplastic Process" abbrv="">childhood AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> associated with <z:mp ids='MP_0004026'>monosomy</z:mp> 7, particularly for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in complete remission and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>